Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Tandem Diabetes Care Inc.

Goldman Sachs analyst David Roman maintained a Hold rating on Tandem Diabetes Care today and set a price target of $25.00. Roman covers the Healthc...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TNDM	$19.17	+4.87%	1.13M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TNDM	$19.17	+4.9%	1.13M
3
4
5
6

TNDM

TNDM

Get Tandem Diabetes Care Inc. Data in Excel

Get Tandem Diabetes Care Inc. Data in Excel